The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
-
COMMENTARY/Global Pharmas Enhance Their Presence in Japan
July 13, 2009
-
COMMENTARY/Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
-
COMMENTARY/Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
-
SURVEY/RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
-
COMMENTARY/JSHP to Promote Use of Generics
June 8, 2009
-
COMMENTARY/Combination Drugs Becoming a "Boom"
June 1, 2009
-
COMMENTARY/Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
-
COMMENTARY/Why Does the Use of Generics Not Increase?
April 27, 2009
-
EMTs Allowed to Administer Epipen
April 27, 2009
-
COMMENTARY/Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
-
The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
-
COMMENTARY/Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
-
Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
-
COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
-
COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
-
Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
-
Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…